bioAffinity Technologies Hosts Physician Roundtable on Lung Cancer Diagnostic Integration
Event summary
- bioAffinity Technologies will host a live virtual physician roundtable on April 8, 2026, to discuss integrating CyPath® Lung into pulmonary practice.
- The webinar will feature pulmonologists sharing real-world case studies demonstrating CyPath® Lung’s clinical utility in early lung cancer detection and risk assessment.
- CyPath® Lung has shown 92% sensitivity, 87% specificity, and 88% accuracy in detecting lung cancer in high-risk patients with small indeterminate lung nodules.
- The test uses advanced flow cytometry and AI to analyze cell populations in patient sputum, incorporating a fluorescent porphyrin to identify malignancy.
The big picture
bioAffinity’s physician roundtable underscores the growing emphasis on noninvasive diagnostics in early cancer detection. The event highlights CyPath® Lung’s potential to streamline pulmonary nodule management, a critical area where current diagnostic tools often fall short. As healthcare systems prioritize cost-effective, high-accuracy solutions, bioAffinity’s ability to demonstrate real-world clinical utility will be key to its market positioning.
What we're watching
- Clinical Adoption
- Whether bioAffinity can accelerate physician adoption of CyPath® Lung through targeted educational initiatives.
- Regulatory Dynamics
- How the company navigates CLIA oversight as it scales CyPath® Lung’s commercialization.
- Competitive Positioning
- The pace at which bioAffinity can differentiate CyPath® Lung in a crowded lung cancer diagnostics market.
Related topics